PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR

Blood. 2017 Feb 23;129(8):1039-1041. doi: 10.1182/blood-2016-09-738245. Epub 2016 Dec 28.

Authors

Elise A Chong¹, J Joseph Melenhorst², Simon F Lacey², David E Ambrose², Vanessa Gonzalez², Bruce L Levine², Carl H June², Stephen J Schuster¹

Affiliations

¹ Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.
² Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Blocking / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Humans
Immunotherapy
Lymphoma, Large B-Cell, Diffuse / diagnostic imaging
Lymphoma, Large B-Cell, Diffuse / immunology*
Lymphoma, Large B-Cell, Diffuse / therapy*
Male
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Receptors, Antigen, T-Cell / immunology
T-Lymphocyte Subsets / immunology

Substances

Antibodies, Blocking
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
CTL019 chimeric antigen receptor
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Receptors, Antigen, T-Cell
pembrolizumab